Ask AI
ProCE Banner Activity

Selecting Patients for PARP Inhibitor Therapy: Principles of Genetic Testing

Slideset
Learn how urologists can identify patients with metastatic prostate cancer most likely to benefit from PARP inhibitor therapy with these downloadable slides reviewing why, how, and when to perform genetic testing.

Released: October 17, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Stephen Freedland, MD

Director of the Center for Integrated Research in Cancer and Lifestyle
Urology, Urologic-Oncology
Cedar-Sinai Medical Center

Stephen Freedland, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Pfizer, Sanofi.